Rubicon Research Limited Stock Price Today (NSE: RUBICON)
Fundamental Score
Rubicon Research Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Rubicon Research Limited share price today is ₹1671.20, down 3.54% on NSE/BSE as of 22 September 2026. Rubicon Research Limited (RUBICON) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹27.64K (Cr). The 52-week high for RUBICON share price is ₹1899.00 and the 52-week low is ₹570.75. At a P/E ratio of 94.21x, RUBICON is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 26.97% and a debt-to-equity ratio of 0.20.
Rubicon Research Limited Share Price Chart — NSE/BSE Historical Performance
Rubicon Research Limited share price chart: 12.13% return over the past month. 52-week high ₹1899.00, 52-week low ₹570.75.
Rubicon Research Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1751.10 | ₹1764.30 | ₹1718.50 | ₹1732.60 | 1.91L (Cr) | |
| ₹1778.90 | ₹1827.50 | ₹1736.20 | ₹1751.10 | 4.70L (Cr) | |
| ₹1766.70 | ₹1834.90 | ₹1766.70 | ₹1778.30 | 1.82L (Cr) | |
| ₹1802.00 | ₹1812.30 | ₹1712.10 | ₹1766.70 | 4.16L (Cr) | |
| ₹1852.90 | ₹1880.50 | ₹1805.10 | ₹1815.60 | 2.00L (Cr) | |
| ₹1792.00 | ₹1848.60 | ₹1758.10 | ₹1835.40 | 3.19L (Cr) | |
| ₹1816.10 | ₹1816.20 | ₹1777.00 | ₹1790.00 | 1.43L (Cr) | |
| ₹1868.10 | ₹1868.20 | ₹1792.50 | ₹1810.50 | 1.89L (Cr) | |
| ₹1751.00 | ₹1870.00 | ₹1741.90 | ₹1860.60 | 3.16L (Cr) | |
| ₹1760.10 | ₹1796.10 | ₹1740.50 | ₹1748.40 | 84.25K (Cr) |
Rubicon Research Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1828.60 | ₹1880.50 | ₹1712.10 | ₹1732.60 | -5.25% | |
| ₹1501.20 | ₹1899.00 | ₹1461.60 | ₹1819.60 | +21.21% | |
| ₹1407.00 | ₹1589.70 | ₹1286.30 | ₹1491.00 | +5.97% | |
| ₹1044.30 | ₹1468.70 | ₹1044.30 | ₹1402.90 | +34.34% | |
| ₹970.00 | ₹1020.00 | ₹918.00 | ₹1005.60 | +3.67% | |
| ₹775.55 | ₹983.20 | ₹762.45 | ₹969.95 | +25.07% | |
| ₹773.10 | ₹820.40 | ₹732.05 | ₹772.80 | -0.04% | |
| ₹675.65 | ₹822.00 | ₹665.90 | ₹780.35 | +15.50% | |
| ₹672.30 | ₹697.05 | ₹625.00 | ₹684.25 | +1.78% | |
| ₹658.50 | ₹704.65 | ₹609.25 | ₹680.75 | +3.38% | |
| ₹620.00 | ₹754.80 | ₹607.15 | ₹655.85 | +5.78% | |
| ₹620.00 | ₹639.70 | ₹570.75 | ₹618.15 | -0.30% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Rubicon Research Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Rubicon Research Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of RUBICON across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (26.97%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.35%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (17.18%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (111.83%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (43.49%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (41.00% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (51.96% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.20)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (8.60x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.01)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (59.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 94.21x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (21.44x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-24.28% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-203.81 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Rubicon Research Limited vs Pharmaceuticals Peers
Peer Comparison -
Compare Rubicon Research Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Rubicon Research LimitedRubicon Researc...Selected✓ RUBICON • 544578 | 68/100 | ₹1671.20₹1671 | ₹27638.31₹27638.31 | 94.21Average 94.2 Average | 26.97%Excellent 26.97% Excellent | 28.35%Excellent 28.35% Excellent | 0.20Excellent 0.2 Excellent | 51.96%Excellent 51.96% Excellent | 41.00%Excellent 41.00% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1861.00₹1861 | ₹446509.73₹446509.73 | 36.92Average 36.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9438.50₹9439 | ₹250120.25₹250120.25 | 85.64Average 85.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1117.80₹1118 | ₹111556.44₹111556.44 | 24.91Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1373.30₹1373 | ₹110942.04₹110942.04 | 32.90Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1945.00₹1945 | ₹105078.63₹105078.63 | 96.00Average 96.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1668.40₹1668 | ₹95999.74₹95999.74 | 26.07Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1143.00₹1143 | ₹95440.50₹95440.50 | 29.54Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2077.80₹2078 | ₹95007.40₹95007.40 | 17.17Average 17.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2238.40₹2238 | ₹92445.92₹92445.92 | 45.23Average 45.2 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price446509.73 Cr
- Divi's Laboratories Limited share price250120.25 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price111556.44 Cr
- Cipla Limited share price110942.04 Cr
Rubicon Research Limited Quarterly Performance
Latest quarterly metrics for RUBICON — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
43.49%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
111.83%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
41.00%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
51.96%
Compounded annual net profit growth over 5 years
Rubicon Research Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for RUBICON — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Rubicon Research Limited Financial Statements
Annual income statement, balance sheet and cash flow for Rubicon Research Limited (RUBICON) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Rubicon Research Limited
About RUBICON (Rubicon Research Limited)
Rubicon Research Limited (RUBICON) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with ...a current market capitalisation of ₹27.64K (Cr). Rubicon Research Limited has delivered a Return on Equity (ROE) of 26.97% and a ROCE of 28.35%. The debt-to-equity ratio stands at 0.20, reflecting the company's capital structure. Investors tracking RUBICON share price can monitor key metrics including P/E ratio, promoter holding of 59.99%, and quarterly earnings growth.
Company Details
RUBICON Share Price: Frequently Asked Questions
What is the current share price of Rubicon Research Limited?
Rubicon Research Limited (RUBICON) trades at ₹1671.20 on NSE and BSE. Market cap ₹27.64K (Cr). Educational data only.
What is the P/E ratio of Rubicon Research Limited?
Rubicon Research Limited has a P/E of 94.21x vs industry average 34.89x.
What is the Bull Run score for Rubicon Research Limited?
Rubicon Research Limited has a Bull Run score of 68/100 based on 25+ financial parameters.
Does Rubicon Research Limited pay dividends?
Rubicon Research Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Rubicon Research Limited?
Rubicon Research Limited has ROE of 26.97%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Rubicon Research Limited?
Rubicon Research Limited has debt-to-equity of 0.20.
Is Rubicon Research Limited a good investment?
Bull Run gives Rubicon Research Limited a score of 68/100. This is not investment advice — consult a SEBI-registered advisor.